These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18372441)

  • 41. Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke.
    Min J; Farooq MU
    Postgrad Med; 2016 Aug; 128(6):620-8. PubMed ID: 27263867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cerebral infarction and transient ischemic attack].
    Sahara N; Kuwashiro T; Okada Y
    Nihon Rinsho; 2016 Apr; 74(4):666-70. PubMed ID: 27333757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bleeding risk assessment for stroke patients on antithrombotic therapy.
    Castilla-Guerra L; Fernández-Moreno MDC; de la Vega-Sánchez JM; Leon Jimenez D
    Clin Investig Arterioscler; 2019; 31(6):282-288. PubMed ID: 31005341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medical Management for Secondary Stroke Prevention.
    Kim AS
    Continuum (Minneap Minn); 2020 Apr; 26(2):435-456. PubMed ID: 32224760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antiplatelet therapy in secondary stroke prevention].
    Hirt L; Carrera E
    Rev Med Suisse; 2017 Apr; 13(560):907-910. PubMed ID: 28727358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
    Liao JK
    Circulation; 2007 Mar; 115(12):1615-21. PubMed ID: 17389280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiplatelet therapy for secondary prevention of acute coronary syndrome, transient ischemic attack, and noncardioembolic stroke in an era of cost containment.
    Kessler C; Thomas K; Kao J
    J Investig Med; 2012 Jun; 60(5):792-800. PubMed ID: 22460233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transient ischemic attacks: Part II. Treatment.
    Solenski NJ
    Am Fam Physician; 2004 Apr; 69(7):1681-8. PubMed ID: 15086040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary prevention of atherothrombotic cerebrovascular events.
    Paciaroni M
    Curr Vasc Pharmacol; 2014 May; 12(3):365-72. PubMed ID: 24846225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transient ischemic attack: risk stratification and treatment.
    Cucchiara B; Ross M
    Ann Emerg Med; 2008 Aug; 52(2):S27-39. PubMed ID: 18655916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing recurrent cerebrovascular events in patients with stroke or transient ischemic attack: the current data.
    Bergman D
    J Am Acad Nurse Pract; 2011 Dec; 23(12):659-66. PubMed ID: 22145656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antiplatelet therapy: update in secondary stroke prevention].
    Uchiyama S
    Brain Nerve; 2013 Jul; 65(7):771-82. PubMed ID: 23832980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Antithrombotic therapy in patients with first-ever stroke and known non-rheumatic atrial fibrillation].
    Gandjour J; Zeindler J; Georgiadis D; Baumgartner RW
    Praxis (Bern 1994); 2005 Jan; 94(4):97-104. PubMed ID: 15732803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medical therapy for secondary prevention of stroke.
    Regesta G
    Clin Exp Hypertens; 2002; 24(7-8):555-62. PubMed ID: 12450231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type.
    Fuentes B; Gállego J; Gil-Nuñez A; Morales A; Purroy F; Roquer J; Segura T; Tejada J; Lago A; Díez-Tejedor E; ; Alonso de Leciñana M; Alvarez-Sabin J; Arenillas J; Calleja S; Casado I; Castellanos M; Castillo J; Dávalos A; Díaz-Otero F; Egido JA; López-Fernández JC; Freijo M; García Pastor A; Gilo F; Irimia P; Maestre J; Masjuan J; Martí-Fábregas J; Martínez-Sánchez P; Martínez-Vila E; Molina C; Nombela F; Ribó M; Rodríguez-Yañez M; Rubio F; Serena J; Simal P; Vivancos J;
    Neurologia; 2014 Apr; 29(3):168-83. PubMed ID: 21937151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent clinical trials of antiplatelet therapy in secondary stroke prevention: expectations and results for application in primary care settings.
    Lutsep HL
    Am J Med; 2009 Apr; 122(4 Suppl 2):S21-31. PubMed ID: 19332240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet, anticoagulant and fibrinolytic agents in acute ischaemic stroke and TIA.
    Sandercock P; Lindley R; Wardlaw J
    Br J Hosp Med; 1992 May 20-Jun 2; 47(10):731-7. PubMed ID: 1606457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.
    Bavishi C; Koulova A; Bangalore S; Sawant A; Chatterjee S; Ather S; Valencia J; Sarafoff N; Rubboli A; Airaksinen JK; Lip GY; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):E12-22. PubMed ID: 26354765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.